DailyIQ
|
Sector:HealthcareAll sectors
Last updated 3 minutes ago

BSX·Boston Scientific Corporation

$.
-. (-.%)
After Hours
High
$57.88
Open
$53.00
Market Cap
85.67B
52W High
$109.50
Low
$50.04
P. Close
$57.66
P/E
24.03
52W Low
$52.52
Fwd P/E
69.44
Mean Target
$83.47
Technical Score (1D)
9
SELL
News Sentiment
68
BULLISH
Goldman Sachs has adjusted its price target for Boston Scientific (BSX) to $81 from $84, while maintaining a 'Buy' rating, indicating continued positive analyst sentiment despite a slightly reduced valuation. This follows a more significant price target cut by Bank of America, which lowered its BSX target to $68 from $105, citing broader concerns within the medtech sector. These analyst actions suggest that while individual company prospects may be viewed favorably, the overall medical technology landscape is facing some headwinds. In related news, Rhenman & Partners Asset Management AB has fully divested its $18.1 million stake in Vera Therapeutics. However, BSX remains a significant holding for the firm, representing 4.8% of its assets under management, highlighting continued conviction in Boston Scientific despite portfolio adjustments elsewhere. Investors will be watching for further commentary on the broader medtech outlook and any specific catalysts that could drive BSX's performance in the near term.
Earnings Summary
Boston Scientific Corporation is a global medical device manufacturer specializing in interventional medical specialties, developing and marketing a diverse portfolio of devices for MedSurg and Cardiovascular segments, including gastrointestinal, urological, neurological, and cardiovascular treatments. Operating within the Healthcare sector's Medical Devices industry, the company's offerings address a wide range of medical needs from chronic pain management to complex cardiovascular conditions. Analyzing the most recent earnings data, Boston Scientific demonstrated consistent EPS beats in Q4 2025 (0.80 actual vs. 0.7873 estimate) and Q1 2026 (0.80 actual vs. 0.78722 estimate). Revenue performance showed a slight miss in Q4 2025 (5.286 billion actual vs. 5.333 billion estimate) but a beat in Q1 2026 (5.203 billion actual vs. 5.171 billion estimate). Comparing the last two reported quarters (Q4 2025 and Q1 2026) against the prior two (Q2 2025 and Q3 2025), EPS growth has been steady, with actual EPS consistently at 0.75 for Q1-Q3 2025 and rising to 0.80 for Q4 2025 and Q1 2026. Revenue has shown an upward trend, accelerating from approximately 4.66 billion in Q1 2025 to over 5.2 billion in Q1 2026. Historically, Boston Scientific has shown a positive year-over-year revenue growth trajectory, with actual revenues generally exceeding estimates, although there have been instances of revenue misses, such as in Q4 2025. The company has a pattern of beating EPS estimates in recent quarters, with actual EPS consistently meeting or exceeding analyst expectations. For example, EPS has been reported at 0.70, 0.75, 0.75, 0.75, 0.80, and 0.80 for Q4 2024 through Q1 2026, respectively, often surpassing the estimated figures. Recent news highlights mixed analyst sentiment, with Goldman Sachs maintaining a 'Buy' rating but adjusting its price target downwards, while Bank of America significantly cut its target, suggesting broader medtech sector headwinds. Boston Scientific has also issued voluntary recalls for certain arrhythmia detector devices due to data collection failures, introducing operational risks. Conversely, positive pivotal trial results for the SEISMIQ 4CE Coronary Intravascular Lithotripsy Catheter were announced, reinforcing its position in interventional cardiology, and notable insider buying occurred near the 52-week low. Looking ahead, investors will be watching for the company's ability to navigate potential sector headwinds and address any impacts from product recalls. Key will be the continued successful execution of its product pipeline, as evidenced by the SEISMIQ 4CE trial, and the company's performance against analyst revenue and EPS estimates in upcoming quarters, particularly given the recent insider buying activity and mixed analyst target adjustments.

EPS

EstBeatMiss
$0.65$0.70$0.75$0.80$0.86Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$0.83 - -
Q1'26$0.79$0.80+1.6%
Q4'25$0.79$0.80+1.6%
Q3'25$0.71$0.75+5.1%
Q2'25$0.73$0.75+3.4%
Q1'25$0.67$0.75+11.5%

Revenue

EstBeatMiss
$4.5B$4.8B$5.1B$5.3B$5.6BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$5.5B - -
Q1'26$5.2B$5.2B+0.6%
Q4'25$5.3B$5.3B-0.9%
Q3'25 - $5.1B -
Q2'25 - $5.1B -
Q1'25 - $4.7B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

BSX Stock Snapshot

BSX is currently trading at $57.92, giving Boston Scientific Corporation a market cap of 85.67B and a P/E ratio of 24.0. Today's range spans $50.04–$57.88, with shares opening at $53.00 and moving up $0.26 (0.5%) from the prior close. DailyIQ's technical score sits at 9/100 (SELL) with a news sentiment reading of 68/100.

Over the past year BSX has traded between $52.52 and $109.50 - the current price is +10.3% off the 52-week low and -47.1% from the high. 43 analysts cover the stock with a Buy consensus and a mean 12-month target of $83.47 (range $60.00–$106.00), implying upside of +44.1%.

Boston Scientific Corporation (BSX) is a large-cap in Healthcare with 85.67B in market cap, and the current technical read is bearish. Score: 9/100 (SELL). Sentiment: bullish at 68/100. Price: $57.92 (near 52-week lows). The current P/E ratio stands at 24.0. The 52-week range of $52.52–$109.50 provides the structural context, and the current SELL designation suggests that prior support levels are more important to watch than usual.

When a large-cap Healthcare name with 85.67B in capitalization prints a SELL signal (9/100) alongside bullish news sentiment (68/100), the risk isn't just price depreciation — it's the loss of institutional sponsorship that makes recovery harder. At $57.92 (near 52-week lows in the $52.52–$109.50 range), the structural support levels are where that sponsorship question gets answered.